Genethera Stock Analysis
| GTHR Stock | USD 0.0001 0.00 0.00% |
GeneThera is overvalued with Real Value of 8.4E-5 and Hype Value of 1.0E-4. The main objective of GeneThera pink sheet analysis is to determine its intrinsic value, which is an estimate of what GeneThera is worth, separate from its market price. There are two main types of GeneThera's stock analysis: fundamental analysis and technical analysis.
The GeneThera pink sheet is traded in the USA on PINK Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA.
GeneThera |
GeneThera Pink Sheet Analysis Notes
About 18.0% of the company shares are held by company insiders. The company recorded a loss per share of 0.03. GeneThera last dividend was issued on the 17th of May 2007. The entity had 1:5000 split on the 9th of July 2008. GeneThera, Inc., a biotechnology company, develops molecular assays and therapeutics for the detection and treatment of zoonotic diseases. The companys Molecular RoboticAI Platform and Therapeutic strategy is designed to prevent the spread of disease from animals and allow to better control of zoonotic infectious agents. Genethera operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 2 people.The quote for GeneThera is published daily by the National Quotation Bureau and the company does not need to meet minimum requirements or file with the SEC. To learn more about GeneThera call the company at 720 587 5100 or check out https://www.genethera.net.GeneThera Investment Alerts
| GeneThera generated a negative expected return over the last 90 days | |
| GeneThera has some characteristics of a very speculative penny stock | |
| Net Loss for the year was (1.01 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| GeneThera currently holds about 140.1 K in cash with (8.57 K) of positive cash flow from operations. | |
| Roughly 18.0% of the company shares are held by company insiders |
GeneThera Market Capitalization
The company currently falls under 'Nano-Cap' category with a current market capitalization of 533.53 K. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate GeneThera's market, we take the total number of its shares issued and multiply it by GeneThera's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.Technical Drivers
GeneThera technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices.GeneThera Price Movement Analysis
The output start index for this execution was thirty-five with a total number of output elements of twenty-six. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. GeneThera middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for GeneThera. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
About GeneThera Pink Sheet Analysis
Pink Sheet analysis is the technique used by a trader or investor to examine and evaluate how GeneThera prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling GeneThera shares will generate the highest return on investment. We also built our pink sheet analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Pink Sheet such as GeneThera. By using and applying GeneThera Pink Sheet analysis, traders can create a robust methodology for identifying GeneThera entry and exit points for their positions.
GeneThera, Inc., a biotechnology company, develops molecular assays and therapeutics for the detection and treatment of zoonotic diseases. The companys Molecular RoboticAI Platform and Therapeutic strategy is designed to prevent the spread of disease from animals and allow to better control of zoonotic infectious agents. Genethera operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 2 people.
Be your own money manager
As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our pink sheet analysis tools, you can find out how much better you can do when adding GeneThera to your portfolios without increasing risk or reducing expected return.Did you try this?
Run Technical Analysis Now
Technical AnalysisCheck basic technical indicators and analysis based on most latest market data |
| All Next | Launch Module |
Additional Tools for GeneThera Pink Sheet Analysis
When running GeneThera's price analysis, check to measure GeneThera's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy GeneThera is operating at the current time. Most of GeneThera's value examination focuses on studying past and present price action to predict the probability of GeneThera's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move GeneThera's price. Additionally, you may evaluate how the addition of GeneThera to your portfolios can decrease your overall portfolio volatility.